These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32522210)

  • 21. Barriers and facilitators of HIV and hepatitis C care among people who inject drugs in Nairobi, Kenya: a qualitative study with peer educators.
    Ludwig-Barron NT; Guthrie BL; Mbogo L; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A
    Harm Reduct J; 2021 Dec; 18(1):133. PubMed ID: 34922548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.
    Safo SA; Batchelder A; Peyser D; Litwin AH
    Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using an intersectionality lens to explore barriers and enablers to hepatitis C point-of-care testing: a qualitative study among people who inject drugs and service providers.
    Fontaine G; Presseau J; Bruneau J; Etherington C; Thomas IM; Hung JC; van Allen Z; Patey AM; Kareem A; Mortazhejri S; Høj SB; Boyer-Legault G; Grimshaw JM
    Int J Equity Health; 2024 Jun; 23(1):124. PubMed ID: 38886803
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Using a programmatic mapping approach to plan for HIV prevention and harm reduction interventions for people who inject drugs in three South African cities.
    Scheibe A; Shelly S; Lambert A; Schneider A; Basson R; Medeiros N; Padayachee K; Savva H; Hausler H
    Harm Reduct J; 2017 Jun; 14(1):35. PubMed ID: 28592246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
    Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
    Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expanding conceptualizations of harm reduction: results from a qualitative community-based participatory research study with people who inject drugs.
    Boucher LM; Marshall Z; Martin A; Larose-Hébert K; Flynn JV; Lalonde C; Pineau D; Bigelow J; Rose T; Chase R; Boyd R; Tyndall M; Kendall C
    Harm Reduct J; 2017 May; 14(1):18. PubMed ID: 28494774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study.
    Barocas JA; Brennan MB; Hull SJ; Stokes S; Fangman JJ; Westergaard RP
    Harm Reduct J; 2014 Jan; 11():1. PubMed ID: 24422784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
    Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
    Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A qualitative study of perceived barriers to hepatitis C care among people who did not attend appointments in the non-urban US South.
    Sherbuk JE; Tabackman A; McManus KA; Kemp Knick T; Schexnayder J; Flickinger TE; Dillingham R
    Harm Reduct J; 2020 Sep; 17(1):64. PubMed ID: 32948189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania.
    Zamudio-Haas S; Mahenge B; Saleem H; Mbwambo J; Lambdin BH
    Int J Drug Policy; 2016 Apr; 30():43-51. PubMed ID: 26880500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global policy and access to new hepatitis C therapies for people who inject drugs.
    Doyle JS; Aspinall EJ; Hutchinson SJ; Quinn B; Gore C; Wiktor SZ; Hellard ME
    Int J Drug Policy; 2015 Nov; 26(11):1064-71. PubMed ID: 26118794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 'Not just one box that you tick off' - Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective.
    Marshall AD; Rance J; Grebely J; Treloar C
    Int J Drug Policy; 2022 Apr; 102():103610. PubMed ID: 35151085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access to and use of health and social services among people who inject drugs in two urban areas of Mozambique, 2014: qualitative results from a formative assessment.
    Dengo-Baloi L; Boothe M; Semá Baltazar C; Sathane I; Langa DC; Condula M; Ricardo H; Inguane C; Teodoro E; Gouveia L; Raymond HF; Horth R
    BMC Public Health; 2020 Jun; 20(1):975. PubMed ID: 32571365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study.
    Akiyama MJ; Muller A; Huang O; Lizcano J; Nyakowa M; Riback L; Ross J; Bundi H; Kulabi ES; Mwangi AM; Musyoki H; Cherutich P; Kurth A
    Glob Public Health; 2022 Jun; 17(6):1016-1028. PubMed ID: 33689563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study.
    Marshall AD; Rance J; Dore GJ; Grebely J; Treloar C
    Int J Drug Policy; 2024 Jul; 129():104477. PubMed ID: 38861842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.